Skip to main content
. 2017 May 8;127(6):2392–2406. doi: 10.1172/JCI90825

Figure 3. PARP1i elevated DSBs and triggered dual cellular synthetic lethality in BRCA/DNA-PK–deficient proliferating and quiescent Nalm-6 leukemia cells.

Figure 3

(A) Sensitivity of the indicated cells to olaparib and BMN673. (B and C) Nalm-6 parental cells (gray bars) and RAD54–/– LIG4–/– counterparts (green bars) treated or not with 0.15 μM olaparib for 24 (B) or 48 (C) hours. (B) γ-H2AX–positive Ki67–and Ki67+ cells and (C) dead Ki67– and Ki67+ cells; representative plots are included. Results represent 3 independent experiments. *P < 0.05 in comparison with olaparib-treated parental cells using Student’s t test.